Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis

Blood

Volumn 117, Issue 26, 2011, Pages 7185-

  Deeg, H Joachim ^a   Appelbaum, Frederick R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; HUMAN; LETTER; MORTALITY; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 79959835612     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-349142     Document Type: Letter

References (8)

1. Tefferi A. How I treat myelofibrosis. Blood. 2011;117(13):3494-3504.
2. Kerbauy DMB, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355-365.
3. Rezvani AR, McCune JS, Batchelder A, Storer BE, McDonald GB, Deeg HJ. Low toxicity and mortality with reversed-order conditioning (cyclophosphamide followed by targeted intravenous busulfan) in allogeneic hematopoietic cell transplantation: preliminary results fo a prospective clinical trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):482-483. Abstract 1175.
4. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
5. Scott BL, Gooley TA, Linenberger ML, et al. International working group scores predict post-transplant outcomes in patients with myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):1272. Abstract 3085.
6. Russell JA, Turner AR, Larratt L, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant. 2007;13(3):299-306.
7. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102(2):756-762. (Pubitemid 36842003)
8. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood. 2010;116(23):4762-4770.